Inclusion Criteria:

        For CML patients either:

          -  a. Patients with Ph+ CML in chronic or accelerated phase who were previously treated
             with at least two different tyrosine kinase inhibitors prior to study entry and are
             relapsed, refractory to or intolerant of TKIs as determined by investigators or

          -  b. Patients with CML in chronic or accelerated phase who exhibit relapsed disease
             associated with the presence of the T315I "gatekeeper mutation" after at least one TKI
             are also eligible provided that no other effective therapy exists

        For ALL and CML-BP patients:

          -  Patients with CML BP or Ph+ ALL who have a cytopathologically confirmed diagnosis and
             are relapsed or refractory to at least one prior TKI or intolerant of TKIs. TKI
             failure for Ph+ ALL and CML-BP patients is defined as at least the loss of Molecular
             Response (MR) 4.5 (BCR-ABL ≤ 0.0032%)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

          -  Willingness and ability to comply with all study procedures

          -  Written informed consent obtained prior to any screening procedures

        Exclusion Criteria:

        Wash-out period:

          -  Systemic antineoplastic therapy (including cytotoxic chemotherapy, alfa-interferon and
             toxin immunoconjugates) or any experimental therapy within 14 days or 5 half-lives,
             whichever is shorter, before the first dose of study treatment

          -  Therapy with TKIs as single agent within 5 half-lives before the first dose of study
             treatment

          -  Unconjugated monoclonal antibody therapies within 28 days or 5 half-lives, whichever
             is shorter, before the first dose of study treatment

          -  For patients receiving ABL001 in combination with either nilotinib or imatinib or
             dasatinib, intolerance to nilotinib, imatinib or dasatinib, respectively

          -  Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a
             limited field of radiation for palliation within 1 week of the first dose of study
             treatment.

          -  CNS irradiation for meningeal leukemia, except if radiotherapy occurred > 3 months
             previously. At least four weeks must have elapsed since prophylactic CNS irradiation
             given as part of a front-line therapy regimen for ALL

          -  Major surgery within 2 weeks before the first dose of study treatment

        Other protocol-defined inclusion/exclusion criteria may apply